S-1/A: Functional Brands Inc. Files S-1/A for Nasdaq Direct Listing Amidst Financial Challenges and Strategic Growth Initiatives

Functional Brands Inc. has filed an S-1/A amendment for a direct listing on the Nasdaq Capital Market, seeking to raise $8 million through a private placement to address a significant acquisition debt and fund growth, despite reporting recurring losses and a going concern warning from its auditors.

Summary

• Functional Brands Inc. is pursuing a direct listing on the Nasdaq Capital Market under the symbol MEHA, with an expected trading commencement around July 2025.
• The company will not receive proceeds from the resale of common stock by existing Registered Stockholders in the direct listing.
• Functional Brands plans to raise approximately $8,000,000 in gross proceeds through a private placement of convertible preferred stock, with proceeds intended to cure an existing acquisition debt and fund growth initiatives.
• The company reported a net loss of $126,781 for Q1 2025, a significant decline from a net income of $80,132 in Q1 2024, representing a 258% decrease.
• Net revenue decreased by 8% to $1,590,258 in Q1 2025 from $1,722,499 in Q1 2024, primarily due to lower demand from contract manufacturing customers.
• For the full year 2024, net revenue decreased by 4% to $6,566,455 from $6,820,499 in 2023, but the net loss improved by 55% to $559,356 from $1,241,094 in 2023 due to cost control.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and a significant accumulated deficit of $7,787,711 as of March 31, 2025.
• Functional Brands has a critical outstanding debt of $2,227,366 related to the Kirkman acquisition, due by July 20, 2025, with a Confession of Judgment filed allowing for foreclosure upon default.
• The company operates two main segments: Kirkman (nutraceuticals/supplements) and HempTown Naturals (hemp-derived products), with Kirkman products sold in over 40 countries and the US, and hemp products sold in specific US states.
• Functional Brands launched P2i by Kirkman, a certified prenatal vitamin aligning with FIGO's low-toxicity standards, tested for 24 heavy metals and 120 toxic chemicals.
• The company has an exclusive licensing agreement with 'Trailer Park Boys' for hemp-derived Delta 9 products, effective until December 31, 2025, with royalty rates between 15% and 30% of gross sales.
• A 1-for-18.338622 reverse stock split was effected on January 22, 2025.
• The company is no longer considered a 'controlled company' as its former parent, Hemptown Organics Corp. (HOC), has distributed its shares.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including recurring losses, negative cash flow, and a going concern warning from its auditors. While it has strategic growth plans and unique product offerings, the substantial debt, reliance on a few customers, and the inherent volatility and regulatory uncertainty of its markets present considerable risks. The direct listing itself carries additional volatility risks. The planned capital raise is critical but its success and impact on long-term viability remain uncertain.

Positives

• The company successfully reduced its net loss by 55% from $1,241,094 in 2023 to $559,356 in 2024, and operating loss by 79% in the same period, indicating improved cost control and stabilization efforts.
• The Kirkman brand has a 70+ year history, a loyal consumer base, and maintains high purity and quality standards, including rigorous testing of every batch for heavy metals and microbial contamination.
• The launch of P2i by Kirkman, a certified prenatal vitamin, positions the company uniquely as the only one aligning with FIGO's strict low-toxicity standards, targeting a significant US market of approximately 3.6 million pregnancies annually.
• The company's competitive strengths include manufacturing in an FDA-registered, cGMP-certified facility in Lake Oswego, Oregon, and extensive testing of raw materials for approximately 90 metals and toxins.
• Functional Brands has an exclusive license agreement with 'Trailer Park Boys' for hemp-derived Delta 9 products, offering a unique market entry point for health, wellness, and recreational use.
• The company's total stockholders' equity improved from a deficit of $(118,577) as of December 31, 2024, to a positive equity of $153,014 as of March 31, 2025.
• The company has engaged Joseph Gunnar & Co., LLC as a financial advisor for the direct listing and a placement agent for the $8 million private placement, indicating active steps towards securing necessary capital.

Negatives

• The company reported a significant swing from an operating income of $145,768 in Q1 2024 to an operating loss of $32,099 in Q1 2025, a 122% decrease.
• Net revenue decreased by 8% in Q1 2025 compared to Q1 2024, primarily due to lower demand from contract manufacturing customers.
• The company has suffered recurring losses from operations and has a significant accumulated deficit of $7,787,711 as of March 31, 2025.
• Functional Brands continues to experience negative cash flows from operations, with cash provided by operating activities decreasing by 99% from $248,169 in 2023 to $1,990 in 2024.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• A significant portion of the company's revenue (54% in 2024) is concentrated with two customers (iHerb and OceanSide Health), posing a substantial risk if these relationships are lost.
• The company has a critical outstanding debt of $2,227,366 for the Kirkman acquisition, due by July 20, 2025, with a Confession of Judgment filed that allows the seller to foreclose on assets upon default.
• The hemp industry, in which the company operates, is subject to uncertain and evolving federal, state, and local regulations, which could materially adversely affect the business.
• The direct listing process, unlike a firm-commitment underwritten IPO, lacks a traditional book-building process and predetermined initial public offering price, potentially leading to higher price volatility and uncertain trading volume.
• Most existing stockholders, other than Lock-Up Parties (officers, directors, and 5%+ holders), are not subject to contractual lock-up agreements, potentially leading to an oversupply of shares and downward pressure on the stock price immediately after listing.

Risks

• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and a significant accumulated deficit.
• The company may be unable to effectively manage future growth, facing capacity constraints and pressure on internal systems and controls.
• Additional financing will be required in the future, which may not be available when needed or may be costly and dilutive to existing shareholders.
• The company has a limited operating history, making it difficult to evaluate its proposed business and prospects, with no assurance of achieving a return on shareholders' investment.
• Significant debt may be incurred to finance operations, with no assurance of sufficient funds to repay indebtedness or avoid default.
• Existing events of default under the Asset Purchase Agreement for the Kirkman acquisition, with a balance of $2,227,366 due by July 20, 2025, could lead to foreclosure on company assets.
• The company operates in brand-conscious industries (nutraceuticals, hemp), and any inability to maintain positive brand image or market acceptance could adversely affect revenues and financial results.
• Competition from larger, well-financed manufacturers and distributors in both the hemp and supplement industries may adversely affect distribution relationships and hinder market expansion.
• The company's ability to develop new products to satisfy changing consumer preferences is critical for long-term success in an industry characterized by rapid changes.
• Reduced demand for smokable products may occur due to health concerns and legislative initiatives, including new taxes or regulatory requirements.
• Some products are subject to developing and unpredictable regulations concerning hemp, CBD, CBG, and Delta 9, with potential for material adverse effects from new restrictions or changes in legality.
• The psychedelic therapy industry and market, where some products may be positioned, is relatively new and may not continue to exist or grow as anticipated, facing marketing challenges due to controlled substance status and public perception.
• International expansion efforts would significantly increase operational expenses and regulatory risks.
• Reliance on distributors, retailers, and brokers, many of whom sell competing products, could affect efficient and profitable distribution and marketing.
• Loss of key distributors or retail accounts, particularly the two customers accounting for 54% of 2024 revenue, would significantly harm the business.
• Disruptions within the supply chain, contract manufacturing, or distribution channels due to various factors (e.g., natural disaster, pandemics, raw material shortages) could adversely affect operations.
• Inability to attract and retain key personnel, including the CEO and CFO, could impair future operations.
• Failure to protect trademarks and trade secrets could harm brand reputation and competitive effectiveness.
• Disruptions to information technology systems due to cyber-attacks or failure to upgrade IT systems may materially impair operations.
• Noncompliance with numerous federal, state, and local regulations (e.g., FDA, FTC, environmental, labor) is costly and could result in fines, production stoppages, or reputational damage.
• The direct listing process differs from a traditional IPO, potentially leading to greater price volatility and uncertain trading volume due to the absence of firm-commitment underwriting and a traditional book-building process.
• The company may not be able to satisfy Nasdaq listing requirements or maintain its listing, which could impair shareholders' ability to trade common stock.
• Future sales of common stock by Registered Stockholders and other existing stockholders (many without lock-up agreements) could cause the share price to decline due to potential oversupply.
• Future issuances of preferred stock or additional common stock could dilute existing shareholders and adversely affect the stock price.
• The company has no current plans to pay cash dividends, meaning investors' sole source of gain will be capital appreciation.
• Changes in accounting standards, subjective assumptions, estimates, and judgments by management related to complex accounting matters could significantly affect financial results.
• Global economic, political, and social conditions, including geopolitical instability, may continue to adversely impact the business and results of operations.
• The transition to a new presidential administration in the United States, including potential tariffs, could materially impact the macroeconomic framework.

Future Outlook

Functional Brands aims to become a leader in the nutraceutical space by upholding high quality standards for toxins, metals, and impurities. The company plans to expand its product portfolio to include mushroom-based supplements, strengthen the Kirkman brand by catering to the autism community's specific needs, launch new broad and niche brands like P2i by Kirkman, modernize manufacturing capabilities to enhance output, and significantly increase investment in sales, marketing, and business development. Additionally, the company intends to identify synergistic companies for potential partnerships or acquisitions. Management anticipates cash needs of approximately $3,600,000 for working capital and capital expenditures over the next twelve months, expecting current cash and cash flow to cover only the next six months, thus planning to seek additional equity or debt financing.

Management Comments

• "Our company operates in the nutraceutical supplement industry. We are a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, mental clarity & focus, sleep, prenatal and urinary."
• "Our Kirkman brand operates in 95% of the major subsegments in the supplement industry. Kirkman has a long-standing loyal customer and consumer base due to the rigorous testing of products in compliance with FDA requirements."
• "We are currently the only certified prenatal vitamin in the market that aligns to the FIGO position statement."
• "The decrease in revenue is attributable primarily due to lower demand from contract manufacturing customers."
• "The decrease of $682,039 [in COGS for FY2024] is partially attributable to 4% lower net revenue recorded for the year ended December 31, 2024, as well as tightening control over costs and negotiating better terms with vendors."
• "The increase of selling and marketing costs is the result of the efforts from the Company to acquire more customers through various methods (email blasts, Amazon marketing) and increase of P2i product advertising campaign."
• "The 11% decrease [in G&A for FY2024] was primarily attributed to less consulting expenses incurred during the period."
• "This is the result of the Company’s continuous work to stabilize the company by tightening costs including COGS and G&A."
• "We believe it is imperative that we meet these sales objectives in order to lessen our reliance on external financing in the future."
• "We intend to continually monitor and adjust our operating plan as necessary to respond to developments in our business, our markets and the broader economy."
• "We believe that our current cash and cash flow from operations will only be sufficient to meet anticipated cash needs for the next six months for working capital and capital expenditures."
• "We plan to seek to sell additional equity securities to generate additional cash to continue operations. We may also sell debt securities to generate additional cash."

Industry Context

Functional Brands Inc. operates within the growing nutraceutical and supplement industry, valued at approximately $405.15 billion globally in 2023 and projected to grow at a CAGR of 6.3% to 2030. The U.S. market alone is valued at $95.2 billion, with dietary supplements specifically at $53.6 billion, driven by increasing health awareness and prevalence of non-communicable diseases. The global prenatal vitamin market, where Functional Brands has a unique certified product (P2i by Kirkman), was valued at $542.8 million in 2023 with an 8.5% CAGR projection. The CBD consumer health market, another segment for Functional Brands, was valued at $19.5 billion globally in 2023, with an 18.1% CAGR, influenced by legalization and perceived health benefits. The company's focus on rigorous testing and certifications, particularly for its prenatal vitamin, aligns with increasing consumer demand for product safety and transparency in the supplement industry. However, the hemp and CBD market faces significant regulatory uncertainty, with the FDA still awaiting Congressional direction on CBD regulation, creating a challenging and unpredictable operating environment compared to more established segments.

Comparison to Industry Standards

• Functional Brands' Kirkman brand, established in 1949, boasts over 70 years in the nutraceutical industry, a longevity that surpasses many competitors and fosters a loyal customer base, particularly within the special needs community (autism spectrum disorders) and a network of over 2,000 doctors in 40+ countries.
• The company's P2i by Kirkman prenatal vitamin is highlighted as the 'only certified prenatal vitamin in the market that aligns to the FIGO position statement,' which recommends independent assessment for contaminants, setting a high standard for low-toxicity testing (24 heavy metals, 120 toxic chemicals) that exceeds typical industry requirements.
• While the FDA does not require testing on dietary supplements, Functional Brands states it tests for approximately 90 metals and toxins in raw materials and every batch of finished products, exceeding minimum FDA requirements for dietary ingredients and finished products.
• In the multi-vitamin segment, market leaders include private label store brands, Nature Made, Centrum, One-A-Day, and Nature's Bounty. In the supplement category (e.g., Digestive Health, General Health), leaders are Nature's Bounty, Nature Made, Emergen-C, Baush+Lomb, and Airbourne. Functional Brands competes with these established players, many of whom have substantially greater financial resources and marketing budgets.
• Within the special needs supplement category, Functional Brands' Kirkman brand competes with companies like New Beginnings, Claire Labs, Houston Enzymes, and Lifetrients, which also focus on dietary sensitivities.
• In the hemp industry, competitors like Charlotte's Web, cbdMD, Social CBD, Joy Organics, and MedTerra produce CBD-related products. Functional Brands' 'Trailer Park Boys' licensing agreement offers a unique brand differentiation in this competitive and evolving market.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed by True Health Medical Center, S.C. against Kirkman Group, Inc., James Hall, David Humphries, HTO Nevada, Inc., and HTO Holdings, Inc. is pending in the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois.
• True Health claims Kirkman underpaid royalties prior to the sale of assets to the HTO Parties and contends that the HTO Parties, as purchasers of certain Kirkman assets, should be bound by the royalty agreement terms.
• There is no certain amount of damages alleged against the HTO Parties at this time.
• Discovery, including limited depositions, has been conducted, and True Health has filed a motion for summary judgment against Kirkman, but not against the HTO Parties.
• Briefing on the summary judgment motion is incomplete, and a ruling is expected more than 60 days away.
• Remaining claims in the case will likely require additional discovery, and no trial date has been scheduled.
• Kirkman Group has recently filed a motion for leave to amend its counterclaims against True Health, none of which are alleged against HTO Nevada, but this could lead to further discovery or motion practice, delaying a trial date.

Related Party Transactions

• Functional Brands Inc. acquired HTO Nevada Inc. (dba Kirkman) from Hemptown Organics Corp. (HOC), a related party, on May 19, 2023, through a share exchange agreement. This was retroactively recorded in 2019 as an acquisition under common control.
• The company has an outstanding payable for acquisition of $2,227,366 as of May 28, 2025, owed to David Humphrey (the seller of Kirkman Group Inc. assets), which is due July 20, 2025. This debt is subject to a Sixth Amended Forbearance Agreement and a Confession of Judgment, allowing foreclosure upon default.
• In December 2023, the company entered into a short-term debt facility with a related party (an officer and director of Hemptown Organics Corp.) for $247,634, which is non-interest-bearing and remains outstanding as of March 31, 2025.
• On March 11, 2024, the company executed a loan agreement with a related party for $130,000 at an annual interest rate of 20%, to be paid off in 7 years.
• On March 10, 2025, the company executed another loan agreement with a related party for $225,000 at an annual interest rate of 18%, to be paid off in 4 years.
• The company has an exclusive license agreement with Trailer Park Boys Incorporated (TPB) to market and sell hemp-derived products, effective from July 21, 2021, until December 31, 2025. The company is obligated to pay TPB $700,000 ($550,000 paid to date) and 1,000,000 shares of common stock, plus royalties of 15-30% of gross sales related to the license.

Stakeholder Impact

• **Shareholders:** Existing shareholders face significant dilution risk from future equity issuances, including the planned private placement of convertible preferred stock and performance-based equity awards to management. The direct listing itself carries high volatility risks and the absence of traditional lock-ups for most existing shareholders could lead to an oversupply of shares and downward price pressure. The company's going concern warning and recurring losses pose a direct threat to investment value.
• **Employees:** The company's ability to attract and retain highly qualified employees is crucial for its growth strategy. Staff turnover and the need to provide competitive salaries could impact efficiency and operations. The CEO and CFO have performance-based equity awards, aligning their incentives with company growth and market valuation.
• **Customers:** The company's focus on high purity and quality standards, particularly for the Kirkman brand and the certified P2i prenatal vitamin, aims to build and maintain customer loyalty. However, lower demand from contract manufacturing customers has negatively impacted recent revenue. Concentration of revenue with two major customers (iHerb and OceanSide Health) creates a significant risk if these relationships are disrupted.
• **Suppliers:** The company relies on high-quality suppliers for raw materials and contract manufacturers for hemp-based products. Disruptions in the supply chain, price increases, or suppliers electing to withdraw services due to regulatory uncertainty could adversely affect the company's ability to produce and sell products.
• **Creditors:** The company has significant outstanding debt, including a $2.2 million acquisition payable with a Confession of Judgment, which allows for foreclosure on assets upon default. This indicates a high level of risk for creditors, although the planned private placement aims to address this immediate concern. The company's recurring losses and going concern warning also raise concerns about its ability to service its debt obligations.

Next Steps

• The company expects its common stock to begin trading on the Nasdaq Capital Market under the symbol MEHA on or about July 2025.
• The company intends to use a portion of the proceeds from the private placement to cure the $2,227,366 Existing Default related to the Kirkman acquisition by July 20, 2025.
• Management plans to seek additional equity and/or debt financing to support working capital needs beyond the next six months and to fund strategic initiatives.
• The company aims to strengthen its Kirkman brand by curating its product mix to cater to the specific needs of the autism community.
• Functional Brands plans to launch multiple new brands, including broad and niche offerings, such as the P2i by Kirkman prenatal vitamin and the Golf Mellow brand.
• The company intends to modernize its manufacturing capabilities by reorganizing space and introducing new machinery and equipment to enhance output.
• Significant investment in sales and marketing activities, as well as business development, is planned to increase sales and distribution.
• The company will identify key companies with synergistic strengths for potential partnerships or acquisitions.
• The legal proceeding with True Health Medical Center is ongoing, with potential for additional discovery and motion practice, and no trial date has been scheduled.

Key Dates

Recommendation

Keywords

Nutraceuticals, Supplements, Hemp-derived products, Direct Listing, Nasdaq, Kirkman, P2i by Kirkman, CBD, CBG, Delta 9, SEC Filing, S-1/A, Going Concern, Private Placement, Corporate Governance, Risk Factors, Financial Performance, Health Supplements, Prenatal Vitamins, Cannabinoids, cGMP, FDA Registered, Trailer Park Boys, Shareholders Equity, Accumulated Deficit